Long-Term Progression-Free Survival in 17p Deletion CLL

VJHemOnc recently attended the 2025 ASCO Annual Meeting in Chicago, IL, where we gained insights into the latest advancements in hematologic oncology. In this episode, leading experts Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Alfred Hospital and Monash University, Melbourne, Australia, and Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, share key updates across multiple disease areas. Topics include recent developments in multiple myeloma, myeloproliferative neoplasms (MPNs), non-Hodgkin lymphoma, chronic lymphocytic leukemia, and blastic plasmacytoid dendritic cell neoplasm (BPDCN).

The post Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more! appeared first on VJHemOnc.